Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating for the company in a research report on Thursday, May 2nd.

Minerva Neurosciences Stock Performance

Shares of NERV stock opened at $3.21 on Friday. The firm has a market capitalization of $22.44 million, a price-to-earnings ratio of -0.72 and a beta of 0.15. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49. The company has a 50 day moving average price of $3.06 and a 200 day moving average price of $4.21.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.07. As a group, equities analysts forecast that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.